CA3047876C - Benzimidazole derivatives, preparation methods and uses thereof - Google Patents
Benzimidazole derivatives, preparation methods and uses thereof Download PDFInfo
- Publication number
- CA3047876C CA3047876C CA3047876A CA3047876A CA3047876C CA 3047876 C CA3047876 C CA 3047876C CA 3047876 A CA3047876 A CA 3047876A CA 3047876 A CA3047876 A CA 3047876A CA 3047876 C CA3047876 C CA 3047876C
- Authority
- CA
- Canada
- Prior art keywords
- fluoro
- compound
- pyridin
- methyl
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016111457 | 2016-12-22 | ||
| CNPCT/CN2016/111457 | 2016-12-22 | ||
| CN2017080661 | 2017-04-14 | ||
| CNPCT/CN2017/080661 | 2017-04-14 | ||
| PCT/CN2017/117950 WO2018113771A1 (en) | 2016-12-22 | 2017-12-22 | Benzimidazole derivatives, preparation methods and uses theirof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3047876A1 CA3047876A1 (en) | 2018-06-28 |
| CA3047876C true CA3047876C (en) | 2023-08-29 |
Family
ID=62624617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3047876A Active CA3047876C (en) | 2016-12-22 | 2017-12-22 | Benzimidazole derivatives, preparation methods and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11053238B2 (https=) |
| EP (1) | EP3559000B1 (https=) |
| JP (1) | JP7105781B2 (https=) |
| KR (1) | KR102543603B1 (https=) |
| CN (1) | CN110234652B (https=) |
| AU (1) | AU2017379041B2 (https=) |
| CA (1) | CA3047876C (https=) |
| DK (1) | DK3559000T3 (https=) |
| ES (1) | ES2917377T3 (https=) |
| TW (1) | TWI732083B (https=) |
| WO (1) | WO2018113771A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| TW201920141A (zh) | 2017-08-15 | 2019-06-01 | 中國大陸商北京軒義醫藥科技有限公司 | Cdk4/6抑制劑及其用途 |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| CN113861191B (zh) | 2018-06-21 | 2023-09-19 | 贝达药业股份有限公司 | 抑制cdk4/6活性化合物的晶型及其应用 |
| MA55909A (fr) * | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | Inhibiteurs de cdk |
| CN111138455B (zh) * | 2020-01-16 | 2022-03-04 | 郑州大学 | 一种手性四氢呋喃并恶嗪稠合苯并咪唑衍生物及其制备方法和用途 |
| CN115427414A (zh) * | 2020-04-28 | 2022-12-02 | 贝达药业股份有限公司 | 稠环化合物及其在医药上的应用 |
| KR102269420B1 (ko) | 2020-09-18 | 2021-06-24 | 전용석 | 긴급대피용 마스크장치 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| MX2023008896A (es) * | 2021-02-03 | 2023-08-09 | Tuojie Biotech Shanghai Co Ltd | Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo. |
| CN112979567B (zh) * | 2021-03-05 | 2023-07-18 | 中国医科大学 | Cdk12小分子抑制剂的化合物及其应用 |
| CN117222411B (zh) * | 2021-03-24 | 2026-03-27 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| CN119522226A (zh) * | 2022-08-01 | 2025-02-25 | 江苏恒瑞医药股份有限公司 | 一种稠三环类衍生物的晶型及制备方法 |
| WO2025016439A1 (zh) * | 2023-07-19 | 2025-01-23 | 浙江同源康医药股份有限公司 | 用作cdk2/4蛋白激酶抑制剂的化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| WO2012002527A1 (ja) | 2010-07-02 | 2012-01-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| CA2954298A1 (en) | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| TWI696617B (zh) | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| CN105153119B (zh) | 2015-09-11 | 2019-01-01 | 广州必贝特医药技术有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
-
2017
- 2017-12-22 WO PCT/CN2017/117950 patent/WO2018113771A1/en not_active Ceased
- 2017-12-22 US US16/471,415 patent/US11053238B2/en active Active
- 2017-12-22 EP EP17882916.4A patent/EP3559000B1/en active Active
- 2017-12-22 DK DK17882916.4T patent/DK3559000T3/da active
- 2017-12-22 TW TW106145306A patent/TWI732083B/zh active
- 2017-12-22 CA CA3047876A patent/CA3047876C/en active Active
- 2017-12-22 KR KR1020197020604A patent/KR102543603B1/ko active Active
- 2017-12-22 CN CN201780078241.XA patent/CN110234652B/zh active Active
- 2017-12-22 ES ES17882916T patent/ES2917377T3/es active Active
- 2017-12-22 JP JP2019534709A patent/JP7105781B2/ja active Active
- 2017-12-22 AU AU2017379041A patent/AU2017379041B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3047876A1 (en) | 2018-06-28 |
| CN110234652A (zh) | 2019-09-13 |
| AU2017379041A1 (en) | 2019-07-25 |
| RU2019121937A (ru) | 2021-01-22 |
| AU2017379041B2 (en) | 2021-08-26 |
| TWI732083B (zh) | 2021-07-01 |
| CN110234652B (zh) | 2020-11-10 |
| EP3559000B1 (en) | 2022-03-23 |
| KR102543603B1 (ko) | 2023-06-14 |
| WO2018113771A1 (en) | 2018-06-28 |
| US20210130345A1 (en) | 2021-05-06 |
| EP3559000A1 (en) | 2019-10-30 |
| JP7105781B2 (ja) | 2022-07-25 |
| KR20190114971A (ko) | 2019-10-10 |
| US11053238B2 (en) | 2021-07-06 |
| JP2020504747A (ja) | 2020-02-13 |
| TW201829406A (zh) | 2018-08-16 |
| EP3559000A4 (en) | 2020-05-27 |
| ES2917377T3 (es) | 2022-07-08 |
| DK3559000T3 (da) | 2022-06-07 |
| RU2019121937A3 (https=) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3047876C (en) | Benzimidazole derivatives, preparation methods and uses thereof | |
| ES2904544T3 (es) | Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos | |
| DK3129374T3 (en) | (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER | |
| WO2008039359A2 (en) | Bicyclic pyrimidine kinase inhibitors | |
| ES2994614T3 (en) | Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof | |
| WO2012080284A2 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| AU2017208555B2 (en) | New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | |
| KR102274755B1 (ko) | Ｐｅｒｋ 저해제로서의 신규한 ｎ―（２，３―디히드로―１ｈ―피롤로［２，３―ｂ］피리딘―５―일）―４―퀴나졸린아민 및 ｎ―（２，３―디히드로―１ｈ―인돌―５―일）―４―퀴나졸린아민 유도체 | |
| KR20130128435A (ko) | 인플루엔자 바이러스 복제의 억제제 | |
| CA2655441A1 (en) | New compounds 384 | |
| AU2013344049A1 (en) | ALK kinase inhibitors | |
| TW200831099A (en) | Substituted heteroaryl pyridopyrimidone derivatives | |
| KR20200115583A (ko) | Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도 | |
| CA2895430A1 (en) | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents | |
| CA2982862C (en) | Preparation and use of kinase inhibitor | |
| CA3083624A1 (en) | Exo-aza spiro inhibitors of menin-mll interaction | |
| CN118369322A (zh) | 取代的单环或双环杂环化合物，其制法与医药上的用途 | |
| ES2763344T3 (es) | Inhibidores macrocíclicos de la cinasa RIP2 | |
| CA3014853A1 (en) | Substituted aminopyridine compound, preparation, and use as a fibroblast growth factor receptor kinase inhibitor | |
| JP2023513333A (ja) | キノリニル基ホスフィンオキシド化合物、並びにその組成物及び使用 | |
| EP1934217A1 (en) | New compounds ii | |
| CN106146478B (zh) | 三嗪衍生物类间变性淋巴瘤激酶抑制剂 | |
| RU2779534C2 (ru) | Производные бензимидазола, способы их получения и применения | |
| JP2009073743A (ja) | 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物 | |
| CN116253735B (zh) | 嘧啶并嘧啶酮类化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201015 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241122 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241122 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251125 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251125 |